{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:55:39Z","timestamp":1791017739261,"version":"4.1.0"},"reference-count":323,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018576","name":"University Hospitals Harrington Discovery Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018576","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017921","name":"Discovery Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032645","name":"Hevolution Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020940","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020940","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jconrel.2026.115034","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:45:25Z","timestamp":1779230725000},"page":"115034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From discovery to therapeutic development of monoclonal antibodies"],"prefix":"10.1016","volume":"396","author":[{"given":"Satish","family":"Rojekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol D.","family":"Gholap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha R.","family":"Pallapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rauf","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavimol","family":"Angsantikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagavendra","family":"Kommineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhath","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darya","family":"Vasilyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Parte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Haeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukmani","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Gimenez-Roig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisa","family":"Gumerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uliana","family":"Cheliadinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgii","family":"Pevnev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guzel","family":"Burganova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra","family":"Tumoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mansoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Barak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Fueyo","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki","family":"A.Goosens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Moldavski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Frolinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Lizneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mone","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115034_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biochi.2020.08.019","article-title":"Antibody stability: a key to performance - analysis, influences and improvement","volume":"177","author":"Ma","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.jconrel.2026.115034_bb0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115034_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0020","doi-asserted-by":"crossref","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/abt\/tbaf014","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2024","volume":"8","author":"Strohl","year":"2025","journal-title":"Antibody Ther."},{"key":"10.1016\/j.jconrel.2026.115034_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17121581","article-title":"Strategic combinations of antibody-drug conjugates from 2023 to 2025: from dual therapies to innovative ADC-based regimens","volume":"17","author":"Jang","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115034_bb0035","series-title":"Thera-SAbDab","author":"T.A. Society","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115034_bb0040","first-page":"132","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2023","volume":"7","author":"Strohl","year":"2024","journal-title":"Antibiol. Ther."},{"key":"10.1016\/j.jconrel.2026.115034_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115034_bb0050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/014107680509800403","article-title":"Therapeutic monoclonal antibodies in oncology","volume":"98","author":"Levene","year":"2005","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.jconrel.2026.115034_bb0055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/eji.1830060713","article-title":"Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion","volume":"6","author":"Kohler","year":"1976","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.jconrel.2026.115034_bb0065","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: the past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0070","doi-asserted-by":"crossref","first-page":"9398","DOI":"10.3390\/ijms26199398","article-title":"Monoclonal antibodies as therapeutic agents in autoimmune and neurodegenerative diseases of the central nervous system: current evidence on molecular mechanisms and future directions","volume":"26","author":"Skarlis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies","volume":"38","author":"Harris","year":"2024","journal-title":"Biodrugs"},{"key":"10.1016\/j.jconrel.2026.115034_bb0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/biomedicines13020299","article-title":"Anti-drug antibody response to therapeutic antibodies and potential mitigation strategies","volume":"13","author":"Howard","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2026.115034_bb0085","article-title":"Comparison of \u201cframework Shuffling\u201d and \u201cCDR Grafting\u201d in humanization of a PD-1 murine antibody","volume":"15-2024","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0090","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1080\/19420862.2016.1215786","article-title":"Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody","volume":"8","author":"Apgar","year":"2016","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12931-018-0859-z","article-title":"The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review","volume":"19","author":"Matucci","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"Biodrugs"},{"key":"10.1016\/j.jconrel.2026.115034_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12100999","article-title":"Injectables and depots to prolong drug action of proteins and peptides","volume":"12","author":"Ibeanu","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115034_bb0110","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/abt\/tbab027","article-title":"US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives","volume":"4","author":"Wang","year":"2021","journal-title":"Antibody Ther."},{"key":"10.1016\/j.jconrel.2026.115034_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/antib11020040","article-title":"Discovering novel small molecule compounds for prevention of monoclonal antibody self-association","volume":"11","author":"Lui","year":"2022","journal-title":"Antibodies"},{"key":"10.1016\/j.jconrel.2026.115034_bb0120","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/bjc.2013.371","article-title":"Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase, Brit","volume":"109","author":"Shpilberg","year":"2013","journal-title":"J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115034_bb0125","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/19420862.2016.1180491","article-title":"Extending the market exclusivity of therapeutic antibodies through dosage patents","volume":"8","author":"Storz","year":"2016","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0130","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.xphs.2021.11.008","article-title":"Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis?","volume":"111","author":"Jiskoot","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0135","series-title":"Antibodies","first-page":"452","article-title":"Developments and challenges for mab-based therapeutics","author":"Goswami","year":"2013"},{"key":"10.1016\/j.jconrel.2026.115034_bb0140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2017.12.009","article-title":"Fate of PEGylated antibody fragments following delivery to the lungs: influence of delivery site, PEG size and lung inflammation","volume":"272","author":"Patil","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115034_bb0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cocis.2017.08.001","article-title":"PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals","volume":"31","author":"Guichard","year":"2017","journal-title":"Curr. Opin. Colloid"},{"key":"10.1016\/j.jconrel.2026.115034_bb0150","series-title":"Therapeutic Monoclonal Antibodies for respiRATORY diseases: Current Challenges and Perspectives, March 31-April 1, 2016, Tours, France, Mabs-Austin","first-page":"999","volume":"8","author":"Desoubeaux","year":"2016"},{"key":"10.1016\/j.jconrel.2026.115034_bb0155","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1208\/s12248-017-0054-z","article-title":"Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes","volume":"19","author":"Morales","year":"2017","journal-title":"Aaps J."},{"key":"10.1016\/j.jconrel.2026.115034_bb0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2016.11.004","article-title":"The state-of-play and future of antibody therapeutics","volume":"122","author":"Elgundi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115034_bb0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2015.10.012","article-title":"Nanotechnology for protein delivery: overview and perspectives","volume":"240","author":"Yu","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115034_bb0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2018.183","article-title":"Non-invasive delivery strategies for biologics","volume":"18","author":"Anselmo","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115034_bb0175","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jconrel.2017.11.036","article-title":"Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates","volume":"269","author":"Abdelaziz","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115034_bb0180","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1080\/10717544.2022.2120566","article-title":"Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer","volume":"29","author":"Wathoni","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115034_bb0185","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/annonc\/mdu524","article-title":"Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study","volume":"26","author":"Jackisch","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/14737140.2017.1264876","article-title":"Adjuvant trastuzumab: a 10-year overview of its benefit","volume":"17","author":"Lambertini","year":"2017","journal-title":"Expert Rev. Anticancer"},{"key":"10.1016\/j.jconrel.2026.115034_bb0195","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1158\/1078-0432.CCR-20-3474","article-title":"FDA approval summary: pertuzumab, trastuzumab, and hyaluronidase-zzxf injection for subcutaneous use in patients with HER2-positive breast cancer","volume":"27","author":"Gao","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/antib8020036","article-title":"Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation","volume":"8","author":"Sifniotis","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.jconrel.2026.115034_bb0205","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.37765\/ajmc.2020.42899","article-title":"Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies","volume":"26","author":"Whalen","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.jconrel.2026.115034_bb0210","doi-asserted-by":"crossref","first-page":"2211185","DOI":"10.1080\/19420862.2023.2211185","article-title":"High concentration formulation developability approaches and considerations","volume":"15","author":"Zarzar","year":"2023","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0215","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.xphs.2017.06.017","article-title":"A formulation development approach to identify and select stable ultra-high-concentration monoclonal antibody formulations with reduced viscosities","volume":"106","author":"Whitaker","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0220","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.humimm.2010.09.007","article-title":"The state of antibody therapy","volume":"71","author":"ElBakri","year":"2010","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115034_bb0230","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1158\/2326-6066.CIR-14-0029","article-title":"Affinity enhancement of antibodies: how low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell responses","volume":"2","author":"Eisen","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0235","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1021\/acs.molpharmaceut.5b00336","article-title":"Solubility challenges in high concentration monoclonal antibody formulations: relationship with amino acid sequence and intermolecular interactions","volume":"12","author":"Pindrus","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.20727","article-title":"Antibody structure, instability, and formulation","volume":"96","author":"Wang","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0250","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.88898","article-title":"Development and biophysical characterization of a humanized FSH-blocking monoclonal antibody therapeutic formulated at an ultra-high concentration","volume":"12","author":"Rojekar","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.jconrel.2026.115034_bb0325","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.xphs.2023.03.026","article-title":"The evolution of commercial antibody formulations","volume":"112","author":"Mieczkowski","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0330","series-title":"US FDA-approved Therapeutic Antibodies With High-concentration Formulation: Summaries and Perspectives","author":"Wang","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115034_bb0255","first-page":"131","article-title":"Challenges in the development of high protein concentration formulations","volume":"11","author":"Shire","year":"2010","journal-title":"Biotechnol. Pharm. Asp."},{"key":"10.1016\/j.jconrel.2026.115034_bb0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1021\/mp500485w","article-title":"Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations","volume":"12","author":"Buck","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bpj.2012.04.047","article-title":"Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter","volume":"103","author":"Connolly","year":"2012","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2026.115034_bb0270","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1080\/19420862.2016.1222342","article-title":"Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity","volume":"8","author":"Arora","year":"2016","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0275","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/toxsci\/kfw121","article-title":"Subvisible aggregates of immunogenic proteins promote a Th1-type response","volume":"153","author":"Ratanji","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0280","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jps.24237","article-title":"Mechanism of reversible self-association of a monoclonal antibody: role of electrostatic and hydrophobic interactions","volume":"104","author":"Esfandiary","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0285","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s11095-014-1352-0","article-title":"Dipole-dipole interaction in antibody solutions: correlation with viscosity behavior at high concentration","volume":"31","author":"Singh","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0290","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jps.22790","article-title":"Classification of protein aggregates","volume":"101","author":"Narhi","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119523","article-title":"Protein aggregation and immunogenicity of biotherapeutics","volume":"585","author":"Pham","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0300","series-title":"Inspection of Injectable Products for Visible Particulates Guidance for Industry","author":"U. FDA, U.S Food and Drug Administration","year":"2021"},{"key":"10.1016\/j.jconrel.2026.115034_bb0305","series-title":"USP 2012:Particulate Matter in Injections","author":"U. FDA","year":"2012"},{"key":"10.1016\/j.jconrel.2026.115034_bb0310","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1016\/j.xphs.2017.08.011","article-title":"Effect of polysorbate 20 and polysorbate 80 on the higher-order structure of a monoclonal antibody and its Fab and Fc fragments probed using 2D nuclear magnetic resonance spectroscopy","volume":"106","author":"Singh","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0315","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/j.xphs.2021.05.012","article-title":"Polysorbate degradation and particle formation in a high concentration mAb: formulation strategies to minimize effect of enzymatic polysorbate degradation","volume":"110","author":"Roy","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0320","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","article-title":"Subcutaneous delivery of monoclonal antibodies: How do we get there?","volume":"286","author":"Viola","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115034_bb0335","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","article-title":"Developments in therapy with monoclonal antibodies and related proteins","volume":"17","author":"Shepard","year":"2017","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.jconrel.2026.115034_bb0345","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1021\/jf048923r","article-title":"Effects of pulsed electric fields and heat treatment on stability and secondary structure of bovine immunoglobulin G","volume":"53","author":"Li","year":"2005","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.jconrel.2026.115034_bb0350","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0167-4838(99)00046-1","article-title":"Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB4-1 and its Fab and Fc fragments","volume":"1431","author":"Welfle","year":"1999","journal-title":"BBA Protein Struct. M."},{"key":"10.1016\/j.jconrel.2026.115034_bb0355","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-5173(99)00152-0","article-title":"Instability, stabilization, and formulation of liquid protein pharmaceuticals","volume":"185","author":"Wei","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0360","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/nyas.14952","article-title":"Optimizing a therapeutic humanized follicle-stimulating hormone-blocking antibody formulation by protein thermal shift assay","volume":"1521","author":"Sant","year":"2023","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0365","doi-asserted-by":"crossref","first-page":"P49","DOI":"10.1186\/1753-6561-7-S6-P49","article-title":"Scale-up considerations for monoclonal antibody production process: an oxygen transfer flux approach","volume":"7","author":"Gimenez","year":"2013","journal-title":"BMC Proc."},{"key":"10.1016\/j.jconrel.2026.115034_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101653","article-title":"Low shear stress increases recombinant protein production and high shear stress increases apoptosis in human cells","volume":"23","author":"Zhan","year":"2020","journal-title":"Iscience"},{"key":"10.1016\/j.jconrel.2026.115034_bb0375","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/(SICI)1097-0290(19980820)59:4<517::AID-BIT15>3.0.CO;2-6","article-title":"Stability of a single-chain Fv antibody fragment when exposed to a high shear environment combined with air-liquid interfaces","volume":"59","author":"Harrison","year":"1998","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2026.115034_bb0380","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-019-0312-3","article-title":"Interfacial stress in the development of biologics: fundamental understanding, current practice, and future perspective","volume":"21","author":"Li","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.115034_bb0385","series-title":"Therapeutic Antibodies: Methods and Protocols","first-page":"57","article-title":"Assessment of therapeutic antibodytherapeutic antibodies developabilitydevelopability by combinations of in vitro and in silicoin silico methods","author":"Wolf P\u00e9rez","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115034_bb0390","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-1-4939-9929-3_21","article-title":"Physical stability studies of antibody-drug conjugates (ADCs) under stressed conditions","volume":"2078","author":"Adem","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0395","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11095-023-03649-z","article-title":"Antibody-drug conjugate overview: a state-of-the-art manufacturing process and control strategy","volume":"41","author":"Li","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124211","article-title":"Antibody-drug conjugates: a promising breakthrough in cancer therapy","volume":"659","author":"Parit","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0405","series-title":"Cryopreservation and Freeze-Drying Protocols","first-page":"59","article-title":"Lyophilization of proteins","author":"Matejtschuk","year":"2007"},{"key":"10.1016\/j.jconrel.2026.115034_bb0410","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4161\/mabs.2.1.10787","article-title":"Cold denaturation of monoclonal antibodies","volume":"2","author":"Lazar","year":"2010","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0415","series-title":"Lyophilization Strategies for Development of a High-Concentration Monoclonal Antibody Formulation: Benefits and Pitfalls","author":"Review","year":"2024"},{"key":"10.1016\/j.jconrel.2026.115034_bb0420","series-title":"Best Practices in Formulation and Lyophilization Development [accessed on: 26 August 2024]","author":"Baxter","year":"2021"},{"key":"10.1016\/j.jconrel.2026.115034_bb0425","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1039\/D1CB00067E","article-title":"Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies","volume":"2","author":"Lundahl","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2025.101092","article-title":"Acute interstitial nephritis induced by monoclonal antibodies targeting calcitonin gene-related peptide (CGRP)&#x2014;unveiling a new association: a case report","volume":"7","author":"Vargas-Brochero","year":"2025","journal-title":"Kidney Med."},{"key":"10.1016\/j.jconrel.2026.115034_bb0435","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0440","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115034_bb0445","series-title":"Guideline for the Production and Quality Control of Monoclonal Antibodies and Related Products Intended for Medicinal Use","author":"W.H.O. (WHO)","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115034_bb0450","series-title":"Workflow for Antibody and Fragment Analysis of Adalimumab (Humira)","author":"Sigma","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115034_bb0455","series-title":"FDA Perspectives on Specs and Effective Control Strategies","article-title":"Aggregates in MAbs and recombinant therapeutic proteins: a regulatory perspective","author":"Cordoba-Rodriguez","year":"2008"},{"key":"10.1016\/j.jconrel.2026.115034_bb0460","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1016\/j.xphs.2021.05.005","article-title":"Characterization of opalescence in low volume monoclonal antibody solutions enabled by microscale nephelometry","volume":"110","author":"Kingsbury","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0465","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1023\/B:PHAM.0000032993.98705.73","article-title":"Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association","volume":"21","author":"Sukumar","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0470","doi-asserted-by":"crossref","first-page":"28971","DOI":"10.1073\/pnas.2014588117","article-title":"First-in-class humanized FSH blocking antibody targets bone and fat","volume":"117","author":"Gera","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.jconrel.2026.115034_bb0475","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cell.2006.01.051","article-title":"FSH directly regulates bone mass","volume":"125","author":"Sun","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115034_bb0480","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/1520-6017(200103)90:3<310::AID-JPS6>3.0.CO;2-R","article-title":"A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody","volume":"90","author":"Cleland","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0485","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1211\/jpp.61.11.0016","article-title":"The relation between moisture-induced aggregation and structural changes in lyophilized insulin","volume":"61","author":"Flores-Fern\u00e1ndez","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115034_bb0490","first-page":"31","article-title":"Lyophilization strategies for development of a high-concentration monoclonal antibody formulation: benefits and pitfalls","volume":"13","author":"Blue","year":"2010","journal-title":"Am. Pharm. Rev."},{"key":"10.1016\/j.jconrel.2026.115034_bb0495","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1023\/A:1012144810067","article-title":"Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody","volume":"14","author":"Duddu","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0500","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1023\/A:1015894409623","article-title":"Identification of sites of degradation in a therapeutic monoclonal-antibody by peptide-mapping","volume":"9","author":"Kroon","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0505","series-title":"Development of Biopharmaceutical Drug-Device Products","first-page":"3","article-title":"Chapter 1: monoclonal antibodies: structure, physicochemical stability, and protein engineering","author":"Mills","year":"2020"},{"key":"10.1016\/j.jconrel.2026.115034_bb0510","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1021\/ac0500582","article-title":"Characterization of a novel modification to monoclonal antibodies: thioether cross-link of heavy and light chains","volume":"77","author":"Tous","year":"2005","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2026.115034_bb0515","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1018905927544","article-title":"The influence of sucrose, dextran, and hydroxypropyl-beta-cyclodextrin as lyoprotectants for a freeze-dried mouse Igg2a monoclonal-antibody (Mn12)","volume":"9","author":"Ressing","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0520","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejpb.2021.01.011","article-title":"Photoinduced cross-linking of formulation buffer amino acids to monoclonal antibodies","volume":"160","author":"Powell","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0525","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/bit.26265","article-title":"Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability","volume":"114","author":"Chung","year":"2017","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2026.115034_bb0530","series-title":"BioProcess International","article-title":"Novel excipients prevent aggregation in manufacturing and formulation of protein and peptide therapeutics","author":"Maggio","year":"2008"},{"key":"10.1016\/j.jconrel.2026.115034_bb0535","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1023\/A:1013054431517","article-title":"Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation","volume":"18","author":"Breen","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0540","doi-asserted-by":"crossref","DOI":"10.1208\/ps050210","article-title":"Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations","volume":"5","author":"Andya","year":"2003","journal-title":"AAPS Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0545","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1023\/A:1018805232453","article-title":"The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody","volume":"16","author":"Andya","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0550","doi-asserted-by":"crossref","first-page":"12409","DOI":"10.1073\/pnas.221463198","article-title":"Deamidation of human proteins","volume":"98","author":"Robinson","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.jconrel.2026.115034_bb0555","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.xphs.2021.11.024","article-title":"Oxidation and deamidation of monoclonal antibody products: potential impact on stability, biological activity, and efficacy","volume":"111","author":"Gupta","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0560","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0378-4347(00)00548-X","article-title":"Identification of multiple sources of charge heterogeneity in a recombinant antibody","volume":"752","author":"Harris","year":"2001","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jconrel.2026.115034_bb0565","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijpharm.2005.10.024","article-title":"Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298","volume":"308","author":"Zheng","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0570","doi-asserted-by":"crossref","first-page":"22549","DOI":"10.1016\/S0021-9258(18)54607-X","article-title":"Effects of Amino-acid-sequence, buffers, and ionic-strength on the rate and mechanism of deamidation of asparagine residues in small peptides","volume":"266","author":"Tylercross","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115034_bb0575","series-title":"Method for protection of peptides or proteins against non-enzymatic deamidation","author":"Anderson","year":"2014"},{"key":"10.1016\/j.jconrel.2026.115034_bb0580","series-title":"Stable pH Optimized Formulation of a Modified Antibody","author":"Johnson","year":"2004"},{"key":"10.1016\/j.jconrel.2026.115034_bb0585","series-title":"Stabilized Antibody Formulation","author":"Lam","year":"2000"},{"key":"10.1016\/j.jconrel.2026.115034_bb0590","series-title":"Identification and Quantification of Oxidation Sites on Monoclonal Antibodies Using Capillary Electrophoresis and Quadrupole Time-of-Flight Mass Spectrometry","author":"R.H.a.S.B. CV","year":"2013"},{"key":"10.1016\/j.jconrel.2026.115034_bb0595","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1021\/bi951526c","article-title":"Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity","volume":"35","author":"Cacia","year":"1996","journal-title":"Biochemistry-Us"},{"key":"10.1016\/j.jconrel.2026.115034_bb0600","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4161\/mabs.21328","article-title":"Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies","volume":"4","author":"Du","year":"2012","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0605","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/bit.22933","article-title":"C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo","volume":"108","author":"Cai","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2026.115034_bb0610","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201700476","article-title":"Microheterogeneity of recombinant antibodies: analytics and functional impact","volume":"13","author":"Beyer","year":"2018","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jconrel.2026.115034_bb0615","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/19420862.2015.1046665","article-title":"Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation","volume":"7","author":"van den Bremer","year":"2015","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0620","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0021-9673(94)01255-D","article-title":"Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian-cell culture","volume":"705","author":"Harris","year":"1995","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jconrel.2026.115034_bb0625","series-title":"Formulation, Characterization, and Stability of Protein Drugs: Case Histories: Case Histories","first-page":"1","article-title":"A compendium and hydropathy\/ flexibility analysis of common reactive sites in proteins: reactivity at Asn, Asp, Gin, and Met motifs in neutral pH solution","author":"Powell","year":"2002"},{"key":"10.1016\/j.jconrel.2026.115034_bb0630","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1021\/bp025511z","article-title":"Free sulfhydryl in recombinant monoclonal antibodies","volume":"18","author":"Zhang","year":"2002","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.jconrel.2026.115034_bb0635","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-018-2496-0","article-title":"Fragmentation of a monoclonal antibody by peroxotungstate","volume":"35","author":"Rathnayaka","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0640","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejpb.2022.08.002","article-title":"Impact of various factors on the kinetics of non-enzymatic fragmentation of a monoclonal antibody","volume":"178","author":"Gupta","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0645","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s11095-022-03454-0","article-title":"Unambiguous Identification of Glucose-Induced Glycation in mAbs and other Proteins by NMR spectroscopy","volume":"40","author":"Moises","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0650","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/19420862.2017.1300214","article-title":"Glycation of antibodies: modification, methods and potential effects on biological functions","volume":"9","author":"Wei","year":"2017","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0655","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2249.1994.tb06133.x","article-title":"Glycation of monoclonal-antibodies impairs their ability to bind antigen","volume":"98","author":"Kennedy","year":"1994","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0665","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/(SICI)1097-0290(19980105)57:1<11::AID-BIT2>3.0.CO;2-Y","article-title":"Protein-protein and protein-salt interactions in aqueous protein solutions containing concentrated electrolytes","volume":"57","author":"Curtis","year":"1998","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2026.115034_bb0670","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.xphs.2016.05.021","article-title":"A micro-polyethylene glycol precipitation assay as a relative solubility screening tool for monoclonal antibody design and formulation development","volume":"105","author":"Toprani","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0675","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s11095-021-03119-4","article-title":"Revisit PEG-induced precipitation assay for protein solubility assessment of monoclonal antibody formulations","volume":"38","author":"Scannell","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0680","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/19420862.2019.1589851","article-title":"Development of a high-throughput solubility screening assay for use in antibody discovery","volume":"11","author":"Chai","year":"2019","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0690","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0001-2998(89)80014-5","article-title":"Practical considerations in the production, purification, and formulation of monoclonal-antibodies for immunoscintigraphy and immunotherapy","volume":"19","author":"Bogard","year":"1989","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115034_bb0695","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","article-title":"Structure-immunogenicity relationships of therapeutic proteins","volume":"21","author":"Hermeling","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0700","series-title":"Lessons Learned and Consequences for Protein Drug Development","article-title":"The immunogenicity of biopharmaceuticals","author":"Patten","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115034_bb0705","series-title":"Development of Biopharmaceutical Drug-Device Products","first-page":"265","article-title":"Chapter 12: strategies in the development of formulations for antibody-based therapeutics","author":"Jameel","year":"2020"},{"key":"10.1016\/j.jconrel.2026.115034_bb0775","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ddr.10344","article-title":"Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies","volume":"61","author":"Harris","year":"2004","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0780","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1023\/B:PHAM.0000008042.15988.c0","article-title":"Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms","volume":"20","author":"Chen","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0785","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/jps.20347","article-title":"Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution","volume":"94","author":"Liu","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0770","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1023\/A:1018948901599","article-title":"Chemical and physical stability of chimeric l6, a mouse-human monoclonal-antibody","volume":"11","author":"Paborji","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0790","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ab.2003.10.031","article-title":"Characterization and analysis of thermal denaturation of antibodies by size exclusion high-performance liquid chromatography with quadruple detection","volume":"325","author":"Hartmann","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jconrel.2026.115034_bb0795","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1021\/acs.molpharmaceut.3c00963","article-title":"Unraveling the microscopic mechanism of molecular ion interaction with monoclonal antibodies: impact on protein aggregation","volume":"21","author":"Saurabh","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0800","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/jps.21232","article-title":"Self-buffering antibody formulations","volume":"97","author":"Gokarn","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0805","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11095-020-02919-4","article-title":"A comprehensive scientific survey of excipients used in currently marketed, therapeutic biological drug products","volume":"37","author":"Rao","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0810","doi-asserted-by":"crossref","DOI":"10.3390\/ph17040528","article-title":"Investigation on the combined effect of hydroxypropyl beta-cyclodextrin (HP\u03b2CD) and polysorbate in monoclonal antibody formulation","volume":"17","author":"Huang","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2026.115034_bb0815","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1023\/A:1015108115452","article-title":"Inverse relationship of protein concentration and aggregation","volume":"19","author":"Treuheit","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0820","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/jps.10216","article-title":"Peroxide formation in polysorbate 80 and protein stability","volume":"91","author":"Ha","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0825","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11095-024-03657-7","article-title":"The effects of excipients on freeze-dried monoclonal antibody formulation degradation and sub-visible particle formation during shaking","volume":"41","author":"Jin","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0830","first-page":"160","article-title":"The use of surface-tension measurements in the design of antibody-based product formulations","volume":"45","author":"Levine","year":"1991","journal-title":"J. Parenter. Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123600","article-title":"Interaction between preservatives and a monoclonal antibody in support of multidose formulation development","volume":"648","author":"Karunaratne","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0840","doi-asserted-by":"crossref","DOI":"10.1208\/ps050208","article-title":"Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques","volume":"5","author":"Gupta","year":"2003","journal-title":"AAPS Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0845","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.xphs.2017.02.007","article-title":"Correlating the effects of antimicrobial preservatives on conformational stability, aggregation propensity, and backbone flexibility of an IgG1 mAb","volume":"106","author":"Arora","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0850","series-title":"Chemical Mechanisms and Functional Effects of Degradation of a Therapeutic Monoclonal Antibody","article-title":"Orthoclone OKT3","author":"Rao","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115034_bb0855","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/js970143s","article-title":"Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2","volume":"86","author":"Lam","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0860","first-page":"69","article-title":"The influence of complexing agent and proteins on the corrosion of stainless steels and their metal components","volume":"14","author":"Kocijan","year":"2003","journal-title":"J. Mater. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0710","first-page":"61","article-title":"Development of drug product formulations: molecular design and early candidates screening","volume":"18","author":"Siedler","year":"2015","journal-title":"Aaps Adv. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0715","first-page":"87","article-title":"Approaches for early developability assessment of proteins to guide quality by design of liquid formulations","volume":"18","author":"Perez-Ram\u00edrez","year":"2015","journal-title":"Aaps Adv. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0720","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4161\/mabs.2.3.11788","article-title":"Stability of IgG isotypes in serum","volume":"2","author":"Correia","year":"2010","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb0725","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/1087057114557781","article-title":"High-throughput screening of formulations to optimize the thermal stability of a therapeutic monoclonal antibody","volume":"20","author":"Niedziela-Majka","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.jconrel.2026.115034_bb0730","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1021\/js980175v","article-title":"Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions","volume":"87","author":"Bam","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0735","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1021\/bc400182x","article-title":"Investigation into temperature-induced aggregation of an antibody drug conjugate","volume":"24","author":"Beckley","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.115034_bb0740","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/jps.24430","article-title":"Developability assessment during the selection of novel therapeutic antibodies","volume":"104","author":"Jarasch","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0745","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.xphs.2017.10.017","article-title":"An intercompany perspective on biopharmaceutical drug product robustness studies","volume":"107","author":"Morar-Mitrica","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0750","series-title":"A\u2013Mab: A Case Study in Bioprocess Development, Version 2.1","author":"C.B.W. Group","year":"2009"},{"key":"10.1016\/j.jconrel.2026.115034_bb0755","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11095-012-0914-2","article-title":"Liquid formulations for stabilizing IgMs during physical stress and long-term storage","volume":"30","author":"Mueller","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0760","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99875-9","article-title":"Long-term stability predictions of therapeutic monoclonal antibodies in solution using Arrhenius-based kinetics","volume":"11","author":"Kuzman","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115034_bb0765","series-title":"Modeling Study of Long-Term Stability of the Monoclonal Antibody Infliximab and Biosimilars Using Liquid-chromatography-tandem Mass Spectrometry and Size-exclusion Chromatography-multi-angle Light Scattering","author":"Legrand","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115034_bb0865","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11110616","article-title":"Be aggressive! Amorphous excipients enabling single-step freeze-drying of monoclonal antibody formulations","volume":"11","author":"Haeuser","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115034_bb0870","doi-asserted-by":"crossref","DOI":"10.3390\/pr11051404","article-title":"Effect of the freezing step on primary drying experiments and simulation of lyophilization processes","volume":"11","author":"Juckers","year":"2023","journal-title":"Processes"},{"key":"10.1016\/j.jconrel.2026.115034_bb0875","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpb.2018.06.010","article-title":"Effect of temperature ramp rate during the primary drying process on the properties of amorphous-based lyophilized cake, Part 2: successful lyophilization by adopting a fast ramp rate during primary drying in protein formulations","volume":"130","author":"Ohori","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(00)00423-3","article-title":"Lyophilization and development of solid protein pharmaceuticals","volume":"203","author":"Wang","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0885","series-title":"Principles and Practices of Lyophilization in Product Development and Manufacturing","first-page":"465","article-title":"Principles and practice of lyophilization process and product development: scale-up and technology transfer","author":"Bhambhani","year":"2023"},{"key":"10.1016\/j.jconrel.2026.115034_bb0890","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.xphs.2017.03.014","article-title":"Lyophilized drug product cake appearance: what is acceptable?","volume":"106","author":"Patel","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0895","series-title":"Formulation & Lyophilization Cycle Development of an Adc, in","author":"Saffell-Clemmer","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115034_bb0900","series-title":"Importance of Assessing Mannitol Crystallinity in Lyophilized Drug Products","author":"Inc","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115034_bb0905","series-title":"Lyophilization of Complex Drug Products: Formulation Challenges and Scale-up","author":"Sciences","year":"2020"},{"key":"10.1016\/j.jconrel.2026.115034_bb0910","series-title":"Protein Instability at Interfaces During Drug Product Development: Fundamental Understanding, Evaluation, and Mitigation","first-page":"249","article-title":"Excipients: characterization, purpose, and selection","author":"Jordan","year":"2021"},{"key":"10.1016\/j.jconrel.2026.115034_bb0915","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1021\/acs.molpharmaceut.9b00687","article-title":"Studying excipient modulated physical stability and viscosity of monoclonal antibody formulations using small-angle scattering","volume":"16","author":"Xu","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb0920","series-title":"The Effects of Formulation and Moisture on the Stability of a Freeze-dried Monoclonal Antibody-vinca Conjugate: A Test of the WLF Glass Transition Theory","author":"Roy","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115034_bb0925","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bit.1069","article-title":"Stability of crystalline proteins","volume":"73","author":"Shenoy","year":"2001","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2026.115034_bb1280","article-title":"Role of NMR in high ordered structure characterization of monoclonal antibodies","volume":"22","author":"Tokunaga","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115110","article-title":"NMR spectroscopy as a characterization tool enabling biologics formulation development","volume":"223","author":"Ma","year":"2023","journal-title":"J. Pharmaceut. Biomed."},{"key":"10.1016\/j.jconrel.2026.115034_bb1290","article-title":"Using X-ray diffraction techniques for biomimetic drug development, formulation, and polymorphic characterization","volume":"6","author":"Rodr\u00edguez","year":"2021","journal-title":"Biomimetics-Basel"},{"key":"10.1016\/j.jconrel.2026.115034_bb1295","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25051030","article-title":"Protein X-ray crystallography and drug discovery","volume":"25","author":"Maveyraud","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.115034_bb1300","article-title":"Analytical techniques for the characterization and quantification of monoclonal antibodies","volume":"16","author":"Alhazmi","year":"2023","journal-title":"Pharmaceuticals-Base"},{"key":"10.1016\/j.jconrel.2026.115034_bb1305","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.464862","article-title":"Size exclusion chromatography of biopharmaceutical products: from current practices for proteins to emerging trends for viral vectors, nucleic acids and lipid nanoparticles","volume":"1722","author":"D\u2019Atri","year":"2024","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jconrel.2026.115034_bb1310","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.xphs.2021.03.023","article-title":"Systematic development of a size exclusion chromatography method for a monoclonal antibody with high surface aggregation propensity (SAP) index","volume":"110","author":"Knihtila","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1315","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2022.129833","article-title":"An accelerated antibody aggregation test based on time sequenced dynamic light scattering","volume":"653","author":"Conner","year":"2022","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.jconrel.2026.115034_bb1320","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-023-02529-4","article-title":"Evaluation and screening of biopharmaceuticals using multi-angle dynamic light scattering","volume":"24","author":"Sharma","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2026.115034_bb1325","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/19420862.2017.1421880","article-title":"Monoclonal antibody higher order structure analysis by high throughput protein conformational array","volume":"10","author":"Song","year":"2018","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb1265","doi-asserted-by":"crossref","DOI":"10.1172\/JCI182702","article-title":"Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer\u2019s disease models","volume":"135","author":"Pallapati","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115034_bb1330","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jps.23405","article-title":"High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants","volume":"102","author":"Menzen","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1335","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.bpj.2019.12.037","article-title":"Thermal and chemical unfolding of a monoclonal IgG1 antibody: application of the multistate Zimm-Bragg theory","volume":"118","author":"Garidel","year":"2020","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2026.115034_bb1275","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/1087057114565593","article-title":"Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools","volume":"20","author":"Razinkov","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.jconrel.2026.115034_bb1340","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijpharm.2013.03.058","article-title":"Characterization of antibody-polyol interactions by static light scattering: implications for physical stability of protein formulations","volume":"448","author":"Abbas","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb1345","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462607","article-title":"Separation of charge variants of a monoclonal antibody by overloaded ion exchange chromatography","volume":"1658","author":"Baran","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jconrel.2026.115034_bb1350","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejps.2013.04.019","article-title":"Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements","volume":"49","author":"Neergaard","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1355","series-title":"Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics","first-page":"1","article-title":"Chapter 1 - LC-MS characterization of antibody-based therapeutics: recent highlights and future prospects","author":"Robotham","year":"2020"},{"key":"10.1016\/j.jconrel.2026.115034_bb1360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122540","article-title":"Automated mass spectrometry multi-attribute method analyses for process development and characterization of mAbs","volume":"1166","author":"Song","year":"2021","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jconrel.2026.115034_bb1365","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.xphs.2021.09.021","article-title":"Subvisible particle analysis of 17 monoclonal antibodies approved in China using flow imaging and light obscuration","volume":"111","author":"Guo","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1370","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/jps.22414","article-title":"The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations","volume":"100","author":"Mach","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1375","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/jps.22123","article-title":"Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation","volume":"99","author":"Wuchner","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1380","series-title":"Encyclopedia of Biophysics","first-page":"315","article-title":"Circular dichroism spectroscopy of biomacromolecules","author":"Rodger","year":"2013"},{"key":"10.1016\/j.jconrel.2026.115034_bb1385","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.aca.2020.03.038","article-title":"FTIR spectroscopy as an analytical tool to compare glycosylation in therapeutic monoclonal antibodies","volume":"1112","author":"Derenne","year":"2020","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jconrel.2026.115034_bb1390","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113734","article-title":"Understanding the discrimination and quantification of monoclonal antibodies preparations using Raman spectroscopy","volume":"194","author":"Makki","year":"2021","journal-title":"J. Pharmaceut. Biomed."},{"key":"10.1016\/j.jconrel.2026.115034_bb1395","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1021\/acs.analchem.0c00627","article-title":"Raman spectroscopy to monitor post-translational modifications and degradation in monoclonal antibody therapeutics","volume":"92","author":"McAvan","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2026.115034_bb0930","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10600","article-title":"PEGylated therapeutics in the clinic","volume":"9","author":"Gao","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115034_bb0935","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1042\/bst0300512","article-title":"Formatting antibody fragments to mediate specific therapeutic functions","volume":"30","author":"Weir","year":"2002","journal-title":"Biochem. Soc."},{"key":"10.1016\/j.jconrel.2026.115034_bb0940","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.4049\/jimmunol.1601538","article-title":"First-in-human study in healthy subjects with FR104, a pegylated monoclonal antibody fragment antagonist of CD28","volume":"197","author":"Poirier","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0945","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1021\/js960282u","article-title":"Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice","volume":"86","author":"McIntosh","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb0950","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1039\/C7AN01496A","article-title":"Chemical modification of antibodies enables the formation of stable antibody-gold nanoparticle conjugates for biosensing","volume":"142","author":"Filbrun","year":"2017","journal-title":"Analyst"},{"key":"10.1016\/j.jconrel.2026.115034_bb0955","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1007\/s11095-013-0977-8","article-title":"Aggregation and chemical modification of monoclonal antibodies under upstream processing conditions","volume":"30","author":"Dengl","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb0960","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68253","article-title":"A general approach for stabilizing nanobodies for intracellular expression","volume":"11","author":"Dingus","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.jconrel.2026.115034_bb0965","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37786-1","article-title":"High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike","volume":"14","author":"Tan","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115034_bb0970","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-023-01763-2","article-title":"Efficient evolution of human antibodies from general protein language models","volume":"42","author":"Hie","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115034_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101785","article-title":"Identification of stabilizing point mutations through mutagenesis of destabilized protein libraries","volume":"298","author":"Ahmed","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115034_bb0980","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/sj.bjc.6601759","article-title":"Impact of antibody framework residue V-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme","volume":"90","author":"Krauss","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115034_bb0985","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1517\/14712598.4.7.1029","article-title":"Controlled-release and local delivery of therapeutic antibodies","volume":"4","author":"Grainger","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2026.115034_bb0990","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-025-03195-4","article-title":"Influence of hydrophobic ion pairing on formulation performance of liraglutide in PLGA microspheres","volume":"26","author":"Vitore","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2026.115034_bb0995","article-title":"Affinity-controlled capture and release of engineered monoclonal antibodies by macroporous dextran hydrogels using coiled-coil interactions","volume":"15","author":"Baniahmad","year":"2023","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb1000","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cellimm.2014.01.003","article-title":"PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses","volume":"287","author":"Chen","year":"2014","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.msec.2015.10.096","article-title":"Controlled delivery of antibodies from injectable hydrogels","volume":"59","author":"Fletcher","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2026.115034_bb1010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/00002512-200724070-00006","article-title":"Sustained-release ophthalmic drug delivery systems for treatment of macular disorders - present and future applications","volume":"24","author":"Booth","year":"2007","journal-title":"Drug Aging"},{"key":"10.1016\/j.jconrel.2026.115034_bb1015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41698-025-01131-0","article-title":"The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer","volume":"9","author":"Lin","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-025-00748-5","article-title":"Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)","volume":"11","author":"Huppert","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.jconrel.2026.115034_bb1030","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jconrel.2014.05.057","article-title":"Injectable controlled release depots for large molecules","volume":"190","author":"Schwendeman","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115034_bb1035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040670","article-title":"Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting","volume":"13","author":"Rahim","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2026.115034_bb1040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/17425247.2025.2470224","article-title":"Transmucosal drug delivery: prospects, challenges, advances, and future directions","volume":"22","author":"Brako","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115034_bb1045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11095-020-02844-6","article-title":"Microneedle mediated transdermal delivery of protein, peptide and antibody based therapeutics: current status and future considerations","volume":"37","author":"Kirkby","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb1050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/19420862.2015.1113360","article-title":"Pharmacokinetic properties of IgG and various Fc fusion proteins in mice","volume":"8","author":"Unverdorben","year":"2016","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb1055","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115034_bb1060","doi-asserted-by":"crossref","first-page":"1759915","DOI":"10.3389\/fbioe.2026.1759915","article-title":"Application of nanoparticles in antibody drug delivery","volume":"14","author":"Xiefukaiti","year":"2026","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1070","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00228-025-03915-6","article-title":"Economic evaluation of antibody-drug conjugates (ADCs) in patients with breast cancer: systematic review","volume":"81","author":"Rezaei","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1075","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s10637-025-01525-8","article-title":"Navigating antibody\u2013drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies","volume":"43","author":"Najdi","year":"2025","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.jconrel.2026.115034_bb1085","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: an assurance for controlled delivery of antibody-drug conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115034_bb1090","article-title":"Peptide-drug conjugates as next-generation therapeutics: exploring the potential and clinical progress","volume":"12","author":"Jadhav","year":"2025","journal-title":"Bioengineering-Basel"},{"key":"10.1016\/j.jconrel.2026.115034_bb1095","doi-asserted-by":"crossref","DOI":"10.2174\/0113892010352443250402184623","article-title":"Spray drying: a promising technique for inhalable vaccine development","author":"Vemulapalli","year":"2025","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1100","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1080\/07373937.2021.1903032","article-title":"Progress in spray-drying of protein pharmaceuticals: Literature analysis of trends in formulation and process attributes","volume":"39","author":"Pinto","year":"2021","journal-title":"Dry. Technol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2004.07.010","article-title":"Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G","volume":"59","author":"Maury","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb1110","series-title":"Respiratory Delivery of Biologics, Nucleic Acids, and Vaccines","first-page":"53","article-title":"Dry powder formulation of monoclonal antibodies for pulmonary delivery","author":"Shepard","year":"2023"},{"key":"10.1016\/j.jconrel.2026.115034_bb1115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5731\/pdajpst.2015.01003","article-title":"Manufacturing of high-concentration monoclonal antibody formulations via spray drying\u2014the road to manufacturing scale","volume":"69","author":"Gikanga","year":"2015","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/07373937.2024.2437691","article-title":"Revealing the potential of nano spray drying for effective delivery of pharmaceuticals and biologicals","volume":"43","author":"Jadhav","year":"2025","journal-title":"Dry. Technol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019","volume":"17","author":"Carter","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115034_bb1135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.6920","article-title":"Association of subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in adults With COVID-19","volume":"5","author":"McCreary","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jconrel.2026.115034_bb1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.1993.73.1.1","article-title":"Interstitial-lymphatic mechanisms in the control of extracellular fluid volume","volume":"73","author":"Aukland","year":"1993","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jconrel.2026.115034_bb1145","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Ther. (St. Louis, MO, U. S.)"},{"key":"10.1016\/j.jconrel.2026.115034_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.giant.2024.100323","article-title":"Progress in biomaterials inspired by the extracellular matrix","volume":"19","author":"Chen","year":"2024","journal-title":"Giant"},{"key":"10.1016\/j.jconrel.2026.115034_bb1155","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1021\/acs.biomac.0c00045","article-title":"3D extracellular matrix mimics: fundamental concepts and role of materials chemistry to influence stem cell fate","volume":"21","author":"Nicolas","year":"2020","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.115034_bb1160","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","article-title":"Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge","volume":"167","author":"S\u00e1nchez-F\u00e9lix","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115034_bb1165","doi-asserted-by":"crossref","first-page":"31554","DOI":"10.1038\/s41598-025-15813-z","article-title":"Subcutaneous interstitial pressure measurement during early septic shock: an exploratory study","volume":"15","author":"Dargent","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115034_bb1170","doi-asserted-by":"crossref","first-page":"2285277","DOI":"10.1080\/19420862.2023.2285277","article-title":"Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume","volume":"15","author":"Desai","year":"2023","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115812","article-title":"Challenges and developments in the manufacturing of high-concentration biotherapeutic monoclonal antibodies","volume":"232","author":"Rathore","year":"2026","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115034_bb1180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-025-00755-9","article-title":"Clinical qualification of subcutaneous injection devices for monoclonal antibodies","volume":"40","author":"Bittner","year":"2026","journal-title":"Biodrugs"},{"key":"10.1016\/j.jconrel.2026.115034_bb1185","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-020-00465-4","article-title":"Immunogenicity challenges associated with subcutaneous delivery of therapeutic proteins","volume":"35","author":"Jarvi","year":"2021","journal-title":"Biodrugs"},{"key":"10.1016\/j.jconrel.2026.115034_bb1190","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.matt.2021.02.025","article-title":"Biomaterial-based immunoengineering to fight COVID-19 and infectious diseases","volume":"4","author":"Zarubova","year":"2021","journal-title":"Matter"},{"key":"10.1016\/j.jconrel.2026.115034_bb1195","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1080\/17425247.2021.1981286","article-title":"Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery","volume":"18","author":"Knowles","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115034_bb1200","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/pharmaceutics17091183","article-title":"Formulation of recombinant therapeutic proteins: technological innovation, regulations, and evolution towards buffer-free formulations","volume":"17","author":"Bas","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115034_bb1205","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1021\/acs.jcim.3c01898","article-title":"Optimizing excipient properties to prevent aggregation in biopharmaceutical formulations","volume":"64","author":"King","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.jconrel.2026.115034_bb1210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3934\/biophy.2025006","article-title":"Subcutaneous sustained-release drug delivery system for antibodies and proteins","volume":"12","author":"Yoshida","year":"2025","journal-title":"AIMS Biophys."},{"key":"10.1016\/j.jconrel.2026.115034_bb1215","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115049","article-title":"Emerging frontiers in drug delivery with special focus on novel techniques for targeted therapies","volume":"165","author":"Yu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2026.115034_bb1220","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.3390\/molecules26195905","article-title":"Controlled drug delivery systems: current status and future directions","volume":"26","author":"Adepu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.115034_bb1225","first-page":"1","article-title":"Wearable devices for subcutaneous delivery of large-volume biologics: design, use, and regulatory perspective","volume":"12","author":"Sunstrom","year":"2025","journal-title":"Biomed. Mater. Devices"},{"key":"10.1016\/j.jconrel.2026.115034_bb1230","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103914","article-title":"Development roadmap for subcutaneous delivery of high dose biologics - high concentration formulation, analytical comparability and patient preference considerations for large volume devices","volume":"114","author":"Ghosh","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1235","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/jps.24444","article-title":"Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins","volume":"104","author":"Liu","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1240","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2022.339828","article-title":"N-Glycosylation of monoclonal antibody therapeutics: a comprehensive review on significance and characterization","volume":"1209","author":"Shrivastava","year":"2022","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jconrel.2026.115034_bb1245","doi-asserted-by":"crossref","DOI":"10.3390\/antib9020022","article-title":"Principles of -linked glycosylation variations of IgG-based therapeutics: pharmacokinetic and functional considerations","volume":"9","author":"Boune","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.jconrel.2026.115034_bb1250","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/imm.13481","article-title":"Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity","volume":"166","author":"Wolf","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2026.115034_bb1255","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/jps.22384","article-title":"Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis","volume":"100","author":"He","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1260","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/jps.21955","article-title":"High throughput thermostability screening of monoclonal antibody formulations","volume":"99","author":"He","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1270","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semnephrol.2012.12.008","article-title":"The adipose tissue as an endocrine organ","volume":"33","author":"Adamczak","year":"2013","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1400","doi-asserted-by":"crossref","DOI":"10.1186\/ar3147","article-title":"The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review","volume":"12","author":"Krieckaert","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2026.115034_bb1405","volume":"12","author":"Moots","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.115034_bb1410","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2026.115034_bb1415","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.115034_bb1420","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.jconrel.2026.115034_bb1425","first-page":"556","article-title":"Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases (vol 11, pg 241-254, 2019)","volume":"11","author":"Talotta","year":"2019","journal-title":"Immunotherapy-Uk"},{"key":"10.1016\/j.jconrel.2026.115034_bb1430","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1084\/jem.20052036","article-title":"T-independent type II immune responses generate memory B cells","volume":"203","author":"Obukhanych","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115034_bb1435","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1034\/j.1600-065X.2000.00607.x","article-title":"B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms","volume":"176","author":"Vos","year":"2000","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2026.115034_bb1440","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.4049\/jimmunol.0802317","article-title":"T-independent antibody responses to T-dependent antigens: a novel follicular dendritic cell-dependent activity","volume":"182","author":"El Shikh","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1445","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-025-03189-2","article-title":"Exploring protein aggregation in biological products: from mechanistic understanding to practical solutions","volume":"26","author":"Rojekar","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2026.115034_bb1480","series-title":"Sauna, Immunogenicity of Protein-based Therapeutics","author":"Zuben","year":"2024"},{"key":"10.1016\/j.jconrel.2026.115034_bb1450","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-023-00820-7","article-title":"Survey outcome on immunogenicity risk assessment tools for biotherapeutics: an insight into consensus on methods, application, and utility in drug development","volume":"25","author":"Gokemeijer","year":"2023","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.115034_bb1455","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12929-025-01190-2","article-title":"Technological advancements in antibody-based therapeutics for treatment of diseases","volume":"32","author":"Lu","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1460","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108805","article-title":"Understanding the molecular bridges between the drugs and immune cell","volume":"267","author":"Dash","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2026.115034_bb1465","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12672-025-04361-7","article-title":"Immune checkpoint blockade in cancer: current insights and future horizons","volume":"17","author":"Saman","year":"2026","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1470","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11936-025-01134-x","article-title":"Advances in cancer immunotherapy regulators of immune checkpoints and effects on the heart","volume":"28","author":"Iqbal","year":"2026","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.jconrel.2026.115034_bb1475","article-title":"The role of immune checkpoint inhibitors in cancer therapy: mechanism and therapeutic advances","volume":"6","author":"Chen","year":"2025","journal-title":"Medcomm"},{"key":"10.1016\/j.jconrel.2026.115034_bb1485","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.3390\/ijms25115972","article-title":"Thymic stromal lymphopoietin and tezepelumab in airway diseases: from physiological role to target therapy","volume":"25","author":"Bagnasco","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1490","article-title":"Modulation of signaling mediated by TSLP and IL-7 in inflammation, autoimmune diseases, and cancer","volume":"11-2020","author":"Markovi\u0107","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1495","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/pharmaceutics15020648","article-title":"Naxitamab activity in neuroblastoma cells is enhanced by nanofenretinide and nanospermidine","volume":"15","author":"Galassi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115034_bb1500","article-title":"Antibody conjugates in neuroblastoma: a step forward in precision medicine","volume":"15-2025","author":"Balla","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1505","first-page":"303","article-title":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115034_bb1510","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3324\/haematol.2023.284197","article-title":"Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy","volume":"109","author":"Tarantelli","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2026.115034_bb1515","series-title":"Depth Analysis of Recent Research Progress, Bioconjugate Chem","first-page":"1951","article-title":"The evolving landscape of antibody\u2013drug conjugates","volume":"34","author":"Sasso","year":"2023"},{"key":"10.1016\/j.jconrel.2026.115034_bb1520","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia\u2014brief report","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1525","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.3390\/molecules28186438","article-title":"Therapeutic antibodies in medicine","volume":"28","author":"Sharma","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.115034_bb1530","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease","volume":"38","author":"Cummings","year":"2024","journal-title":"Biodrugs"},{"key":"10.1016\/j.jconrel.2026.115034_bb1535","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115034_bb1540","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115034_bb1545","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/imr.13380","article-title":"Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways","volume":"328","author":"Eggel","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2026.115034_bb1550","doi-asserted-by":"crossref","first-page":"886","DOI":"10.4049\/immunohorizons.2300102","article-title":"Recent advances in the development of monoclonal antibodies and next-generation antibodies","volume":"7","author":"Singh","year":"2023","journal-title":"ImmunoHorizons"},{"key":"10.1016\/j.jconrel.2026.115034_bb1555","first-page":"12","article-title":"Monoclonal antibodies in modern medicine: their therapeutic potential and future directions, trends","volume":"2","author":"Samuel Ebele","year":"2024","journal-title":"Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1560","article-title":"Monoclonal antibodies: trends in therapeutic success and commercial focus","volume":"28","author":"Kinch","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.115034_bb1565","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/s41589-025-01950-z","article-title":"Harnessing computational technologies to facilitate antibody\u2013drug conjugate development","volume":"21","author":"Croitoru","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1570","doi-asserted-by":"crossref","first-page":"2505092","DOI":"10.1080\/19420862.2025.2505092","article-title":"Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies","volume":"17","author":"Brennan","year":"2025","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.jconrel.2026.115034_bb1575","doi-asserted-by":"crossref","DOI":"10.1002\/pro.70351","article-title":"Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A","volume":"34","author":"Kato","year":"2025","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1580","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.3390\/molecules29245923","article-title":"The application of machine learning on antibody discovery and optimization","volume":"29","author":"Zheng","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.115034_bb1585","first-page":"25","article-title":"Integrating artificial intelligence into small molecule development for precision cancer immunomodulation therapy, npj","volume":"2","author":"Sutanto","year":"2025","journal-title":"Drug Des. Discov."},{"key":"10.1016\/j.jconrel.2026.115034_bb1590","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.3390\/jcm13216537","article-title":"Next-generation immunotherapy: advancing clinical applications in cancer treatment","volume":"13","author":"Garg","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2026.115034_bb1595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antib15010001","article-title":"Nanobody therapeutics in Alzheimer\u2019s disease: from molecular mechanisms to translational approaches","volume":"15","author":"Godugu","year":"2026","journal-title":"Antibodies"},{"key":"10.1016\/j.jconrel.2026.115034_bb1600","doi-asserted-by":"crossref","first-page":"8305","DOI":"10.3390\/ijms21218305","article-title":"Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies?","volume":"21","author":"Hosseinkhani","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115034_bb1605","article-title":"From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases","volume":"16-2025","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1610","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuron.2024.12.006","article-title":"Toward curing neurological autoimmune disorders: biomarkers, immunological mechanisms, and therapeutic targets","volume":"113","author":"Segal","year":"2025","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2026.115034_bb1615","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/antib11030056","article-title":"Alternative routes of administration for therapeutic antibodies\u2014state of the art","volume":"11","author":"Pitiot","year":"2022","journal-title":"Antibodies"},{"key":"10.1016\/j.jconrel.2026.115034_bb1620","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124877","article-title":"Novel strategies in systemic and local administration of therapeutic monoclonal antibodies","volume":"667","author":"Pra\u0161nikar","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115034_bb1630","doi-asserted-by":"crossref","DOI":"10.1016\/j.nxnano.2026.100371","article-title":"The chemo-biochemical convergence in nanomedicine: a review of tailored therapeutic strategies","volume":"9","author":"Marriam","year":"2026","journal-title":"Next Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1635","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2024.101922","article-title":"Enhancing complement activation by therapeutic anti-tumor antibodies: mechanisms, strategies, and engineering approaches","volume":"77","author":"Ovcinnikovs","year":"2025","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1640","article-title":"Prodrug-based bispecific antibodies for cancer therapy: advances and future directions","volume":"16-2025","author":"Ai","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115034_bb1645","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbrc.2021.06.030","article-title":"High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP","volume":"567","author":"Lee","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.115034_bb1650","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105898","article-title":"Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD","volume":"226","author":"Liu","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2026.115034_bb1655","doi-asserted-by":"crossref","DOI":"10.3390\/md21110550","article-title":"Novel approach for obtaining variable domain of new antigen receptor with different physicochemical properties from Japanese topeshark (Hemitriakis japanica)","volume":"21","author":"Nakada-Masuta","year":"2023","journal-title":"Mar. Drugs"}],"updated-by":[{"DOI":"10.1016\/j.jconrel.2026.115382","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:00:00Z","timestamp":1794268800000}}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:39:35Z","timestamp":1791016775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926004372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":323,"alternative-id":["S0168365926004372"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115034","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From discovery to therapeutic development of monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115034"}}